Navigation Links
Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
Date:6/28/2010

CHENGDU, China, June 28 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics will exhibit and promote its flagship product portfolio at the 45th 2010 National New Special Drugs Trade Fair at Beijing National Convention Center from July 8th, till July 10th. Tianyin's portfolio is featured by the patented Ginkgo Mihuan Oral Liquid (GMOL) for cardiovascular and central nervous system indications, Apu Shuangxin (APU, Benorylate Granules) for fever, inflammation and rheumatism, Xuelian Chongcao Oral Solution (XLCC) for heart diseases, asthma and gynecological conditions, along with other prescription medicines that target high incidence China health care indications.

"Years of sales and marketing efforts by Tianyin Pharmaceutical have established a nationwide network that covers more than 850 hospitals with an in-depth market penetration," said Dr. Jiang, Guoqing. "The network synergizes with our marketing strategies that target high incidence, chronic conditions in a growing aging Chinese population whose health care spending is boosted by an increasing disposable income and health care funding by the government. This synergy is centered on our flagship portfolio such as GMOL, APU, and XLCC etc. that contributes close to 50% of our annual revenue."

About National New Special Drugs Trade Fair

http://www.newdrugschina.com/

The 45th National New Special Drugs Trade Fair gathers the leading pharmaceutical enterprises, elite new drug R&D institutes, the technology transfer organizations, and the biomedical science and technology industrial areas in China to offer a platform for both scientific and commercial collaboration and development. An International new medicine technology transfer and the commercialization collaboration summit will be conducted with the main Trade Fair.

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of- the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

     Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     23rd Floor Unionsun Yangkuo Plaza
     No. 2, Block 3, South Renmin Road
     Chengdu, 610041
     China
     Web:   http://www.tianyinpharma.com
     Email: Dr.Tong@tianyinpharma.com
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +86-134-3655-0011
            +1-949-350-6999 (U.S.)


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
2. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
3. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
5. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
6. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
7. Parata Promotes Sales and Engineering Executives
8. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
9. Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010
10. PLAN C Agency Promotes Hepatitis B Awareness Through B HERE
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, ... in collaboration with the Fertility Center of California, is pleased to announce the ... sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are ...
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is ... of red these days. According to recent estimates, 75 – 80% of the ... errors(1). Some studies point to Electronic Health Records (EHR) with automated features designed ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United ... replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the American ... need to be reconciled in committee, or the House will have to take up ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
Breaking Medicine News(10 mins):